STOCK TITAN

Janux Therapeutics (JANX) EPS by Year

JANX NASDAQ

Janux Therapeutics, Inc. lost $1.83 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $1.64 per diluted share. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Janux Therapeutics, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$1.83
YoY n/m
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

JANX EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
EPS (Diluted)-$1.64-$1.83n/m-$1.28n/m-$1.32n/m-$1.52-$1.39-$7.41

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

JANX EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)-$0.35n/m-$0.39n/m-$0.51n/m-$0.39n/m-$0.55n/m-$0.38n/m-$0.35n/m-$0.51n/m-$0.11n/m-$0.30n/m-$0.24n/m-$0.25n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Janux Therapeutics, Inc. financials

Frequently Asked Questions

What was Janux Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?

Janux Therapeutics, Inc. lost $1.83 per diluted share in fiscal year 2025.

How fast is Janux Therapeutics, Inc.'s diluted earnings per share growing?

Janux Therapeutics, Inc. (JANX) reported a loss of $1.28 per diluted share in fiscal year 2024 and a loss of $1.83 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

What is Janux Therapeutics, Inc.'s diluted earnings per share over the last twelve months?

Janux Therapeutics, Inc. (JANX) reported a loss of $1.64 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 6 fiscal years this page covers, Janux Therapeutics, Inc. (JANX) diluted earnings per share went from -$7.41 in fiscal year 2020 to -$1.83 in fiscal year 2025.

Janux Therapeutics, Inc. (JANX) reported -$0.35 in diluted earnings per share in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Janux Therapeutics, Inc. (JANX) reported on that line in every period on record.